The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. 10 stocks we like better than ...

Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not seen ...

The phase 2 FIGHT trial testing bemarituzumab plus chemotherapy as a front-line therapy for advanced gastric and gastroesophageal junction cancer met all its efficacy objectives, with significant ...

Get the latest Zai Lab Limited (ZLAB) stock news and headlines to help you in your trading and investing decisions.

Find the latest Zai Lab Limited (ZLAB) stock quote, history, news and other vital information to help you with your stock trading and investing.

New data presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) highlight the robust performance of a tissue-free molecular residual disease (MRD) assay, Latitude, in ...

8 July 2025 US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though analysts pledged to wait for more data on safety and tolerability before assessing ...